{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000010","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.982437+00:00","generated_at":"2026-06-06T10:51:14.067886+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora Pharmaceuticals announces $15M private placement with potential $30M from warrant exercises","bullets":["Upfront gross proceeds of $15M from sale of shares and pre-funded warrants at $0.5524 per unit.","Tranche A warrants (24.7M shares, $0.6076 exercise) tied to KIO-301 Phase 2 data; Tranche B tied to KIO-104 Phase 2.","Participating investors include ADAR1 Capital, Nantahala Capital, Rosalind Advisors, Stonepine Capital, Velan Capital.","Net proceeds to fund KIO-104 development for posterior non-infectious uveitis and general operations.","Closing expected on or about February 5, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000010","json":"https://secwatch.observer/filing/0001372514-24-000010.json","markdown":"https://secwatch.observer/filing/0001372514-24-000010.md","text":"https://secwatch.observer/filing/0001372514-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/0001372514-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/kprx-20240131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:51:14.067886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79d0e925de0cc62c1096210dd650bb046a3efecf","claim":"KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at approximately $15.0 million (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/0001372514-24-000010-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $15.0 million"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"},{"claim_id":"d0f3e480f73a98811d7033359017c4675d3c106d","claim":"KIORA PHARMACEUTICALS INC entered into Placement Agency Agreement with Maxim Group LLC (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024 and in connection with the Securities Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/0001372514-24-000010-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}